--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the launch of a first-in-human Phase 1 ...

--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies ... investigational medicine, HC002, with the plan to expand to other indications.

December 18, 2024--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies ... of HC002 in healthy adults. HC002 is an investigational, orally ...